Context-dependent activation of SIRT3 is necessary for anchorage-independent survival and metastasis of ovarian cancer cells

Nadine Hempel · 2019-11-13

Tumor cells must alter their antioxidant capacity for maximal metastatic potential. Yet the antioxidant adaptations required for ovarian cancer transcoelomic metastasis, which is the passive dissemination of cells in the peritoneal cavity, remain largely unexplored. Somewhat contradicting the need for oxidant scavenging are previous observations that expression of SIRT3, a nutrient stress sensor and regulator of mitochondrial antioxidant defenses, is often suppressed in many primary tumors. We have discovered that this mitochondrial deacetylase is specifically upregulated in a context-dependent manner in cancer cells. SIRT3 activity and expression transiently increased following ovarian cancer cell detachment and in tumor cells derived from malignant ascites of high-grade serous adenocarcinoma patients. Mechanistically, SIRT3 prevents mitochondrial superoxide surges in detached cells by regulating the manganese superoxide dismutase (SOD2). This mitochondrial stress response is under dual regulation by SIRT3. SIRT3 rapidly increases SOD2 activity as an early adaptation to cellular detachment, which is followed by SIRT3-dependent increases in SOD2 mRNA during sustained anchorage-independence. In addition, SIRT3 inhibits glycolytic capacity in anchorage-independent cells thereby contributing to metabolic changes in response to detachment. While manipulation of SIRT3 expression has few deleterious effects on cancer cells in attached conditions, SIRT3 upregulation and SIRT3-mediated oxidant scavenging are required for anoikis resistance in vitro following matrix detachment, and both SIRT3 and SOD2 are necessary for colonization of the peritoneal cavity in vivo. Our results highlight the novel context-specific, pro-metastatic role of SIRT3 in ovarian cancer.
Journal
Oncogene
Funding

NIH HHS

S10 OD018124

NCI NIH HHS

R01 CA230628

NCATS NIH HHS

TL1 TR002016

NCATS NIH HHS

UL1 TR002014

NCI NIH HHS

R00 CA143229

NIGMS NIH HHS

R01 GM128055

U.S. Department of Health & Human Services | NIH | National Cancer Institute

R00CA143229

U.S. Department of Health & Human Services | NIH | National Cancer Institute

R01CA230628

U.S. Department of Health & Human Services | NIH | National Cancer Institute

Rivkin Center for Ovarian Cancer

United States Department of Defense | United States Army | Army Medical Command | Congressionally Directed Medical Research Programs

W81XWH-16-1-0117

Penn State | Penn State College of Medicine | Penn State Hershey Cancer Institute

Agilent Technologies

U.S. Department of Health & Human Services | National Institutes of Health

S100D018124